ClinConnect ClinConnect Logo
Search / Trial NCT05420259

Combined Exercise and Nutritional Intervention in GI Cancer Patients

Launched by HOSPITAL BEATRIZ ÂNGELO · Jun 13, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Body Composition Wasting Malnutrition

ClinConnect Summary

This clinical trial is studying how a combination of exercise and nutrition can help patients with pancreatic and gastric cancer during their treatment. The researchers want to see if this approach can reduce inflammation, improve the body’s response to chemotherapy, and help maintain muscle mass, which is important for overall health. They believe that focusing on exercise and diet before surgery could be a valuable opportunity to improve patients' wellbeing during their treatment journey.

To participate in this study, patients must be between 40 and 80 years old, have stage II or III gastric or pancreatic cancer, and be able to start neoadjuvant chemotherapy. This means they should be in relatively good health (with a specific performance status) but have not been very active recently. If eligible, participants will engage in a structured program involving exercise and nutritional support. It's important to note that patients with certain health conditions or those on specific medications may not qualify for this trial. Overall, this study aims to provide new insights into how combining exercise with dietary changes could benefit cancer patients during a critical time in their treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • gastric or pancreatic cancer stage II/III, eligible for neoadjuvant chemotherapy,
  • age higher than 40 years and lower than 80 years,
  • ECOG (Eastern Cooperative Oncology Group) functional status: 0-2,
  • sedentary/low physical activity level.
  • Exclusion Criteria:
  • life expectancy less than 12 months at inclusion,
  • chemotherapy regimen other than 5-Fluorouracil, Folinic acid, Oxaliplatin, Docetaxel (FLOT) for gastric and 5-Fluorouracil, Irinotecan and Oxaliplatin (FOLFIRINOX) or gemcitabine for pancreatic cancer,
  • metastatic disease,
  • chronic anti-inflammatory medication use,
  • known inflammatory condition (rheumatoid arthritis, ankylosing spondylitis or chronic active hepatitis)
  • cardiovascular, respiratory or musculoskeletal or joint problems that preclude moderate physical activity.

About Hospital Beatriz ângelo

Hospital Beatriz Ângelo is a leading healthcare institution dedicated to delivering high-quality medical services and advancing clinical research. Located in Portugal, the hospital is committed to improving patient outcomes through innovative treatments and evidence-based practices. As a clinical trial sponsor, Hospital Beatriz Ângelo focuses on fostering collaboration among healthcare professionals, researchers, and academic institutions to facilitate the development of new therapies and enhance the understanding of various medical conditions. With a strong emphasis on patient safety and ethical standards, the hospital plays a pivotal role in contributing to the advancement of medical science and improving healthcare delivery.

Locations

Lisboa, , Portugal

Loures, Lisboa, Portugal

Patients applied

0 patients applied

Trial Officials

Marilia Cravo

Study Director

Hospital da Luz

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials